Hims and Hers beats quarterly profit on steady subscription growth

Hims and Hers Health (HIMS.N) missed second-quarter revenue estimates, reporting $544.8 million against expectations of $551.6 million, primarily due to a 10% year-over-year decline in its wholesale unit sales, which sent shares down 9% in extended trading. The revenue weakness is linked to decreasing wholesale demand and regulatory scrutiny surrounding its 'personalized' semaglutide offerings. Despite the revenue miss, the company surpassed profit estimates with 17 cents per share and grew subscribers by 31% year-over-year, albeit at a slower rate than the previous quarter, raising questions about its long-term growth sustainability amid evolving regulatory landscapes.

Analysis

Hims & Hers Health (HIMS) reported mixed second-quarter results, characterized by a top-line miss counteracted by bottom-line strength, set against a backdrop of significant regulatory risk. The company's revenue of $544.8 million fell short of the $551.6 million analyst consensus, triggering a 9% decline in its shares during extended trading. This revenue weakness was primarily driven by a 10% year-over-year contraction in its wholesale business, which posted sales of just $7.95 million. The results arrive amidst mounting pressure from the U.S. FDA's crackdown on mass-compounded drugs, directly impacting Hims' strategy of offering "personalized" semaglutide, which Novo Nordisk has publicly deemed illegal. This regulatory and legal overhang casts doubt on the sustainability of a key growth initiative. In contrast to the revenue miss, the company demonstrated operational efficiency by delivering a profit of 17 cents per share, exceeding the 15-cent estimate. Furthermore, subscriber growth remains a bright spot, increasing 31% year-over-year to 2.44 million, although this marks a deceleration from the 38% growth reported in the first quarter, signaling potential maturation or headwinds.

Key Decisions for Investors

• Investors should weigh the significant regulatory and legal risks associated with the company's semaglutide offerings against its demonstrated profitability and strong subscriber base.
• The deceleration in subscriber growth from 38% to 31% warrants close monitoring in subsequent quarters to determine if it's a trend or a temporary slowdown.
• Given the 10% decline in the wholesale unit, it is crucial to assess whether this segment's weakness is an isolated issue or a leading indicator of broader demand challenges.